A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 53,082 shares of PCVX stock, worth $2.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,082
Holding current value
$2.25 Million
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$28.04 - $37.2 $1.49 Million - $1.97 Million
53,082 New
53,082 $1.73 Million
Q2 2023

Aug 14, 2023

SELL
$34.66 - $54.07 $235,445 - $367,297
-6,793 Reduced 17.94%
31,068 $1.55 Million
Q1 2023

May 15, 2023

BUY
$36.27 - $47.2 $1.37 Million - $1.79 Million
37,861 New
37,861 $1.42 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $2.51B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.